<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655716</url>
  </required_header>
  <id_info>
    <org_study_id>283852</org_study_id>
    <nct_id>NCT04655716</nct_id>
  </id_info>
  <brief_title>Urine Alkalinisation to Prevent AKI in COVID-19</brief_title>
  <official_title>Urine Alkalinisation to Prevent Acute Kidney Injury in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to explore the feasibility and safety of urine alkalinisation in critically ill&#xD;
      patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute kidney injury appears to a major part of the SARS-CoV-2 syndrome. Preventing&#xD;
      early acute kidney injury may reduce severe AKI as the disease progresses. Urine&#xD;
      alkalinisation to prevent binding of SARS-COV-2 to renal tubular epithelial cells is a novel&#xD;
      concept that could be used to design other therapies to reduce viral binding. Showing&#xD;
      feasibility with this safe and available strategy could be the first step toward other&#xD;
      related efforts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients treated who achieve &gt;50% of urine measurements above pH 7.0 over the duration of intervention</measure>
    <time_frame>up to 10 days after intensive care unit admission</time_frame>
    <description>proportion of patients treated who achieve &gt;50% of urine measurements above pH 7.0 over the duration of intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of days alive and free of stage 2-3 AKI (up to day 28) in each group</measure>
    <time_frame>up to day 28 after randomisation</time_frame>
    <description>number of days alive and free of stage 2-3 AKI (up to day 28) in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients developing stage 2-3 AKI</measure>
    <time_frame>up to day 28 after randomisation</time_frame>
    <description>proportion of patients developing stage 2-3 AKI (or stage 3 if already at stage 2 at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator-free days</measure>
    <time_frame>up to day 28 after randomisation</time_frame>
    <description>ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital-free days</measure>
    <time_frame>up to day 60 after randomisation</time_frame>
    <description>hospital-free days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous sodium bicarbonate infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care by the clinical team</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate 150Meq/L/D5W Inj</intervention_name>
    <description>Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <other_name>8.4% sodium bicarbonate intravenous form</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed Covid-19 positive&#xD;
&#xD;
          -  Admission to Critical Care Unit&#xD;
&#xD;
          -  Bladder catheter in situ&#xD;
&#xD;
          -  Central line in place (including PICC line)&#xD;
&#xD;
          -  Age â‰¥18y&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage 3 AKI (as defined by KDIGO criteria)&#xD;
&#xD;
          -  Chronic kidney disease stage 4 or 5&#xD;
&#xD;
          -  Contraindications to NaHCO3 therapy (e.g. risk of serious drug interaction, systemic&#xD;
             metabolic alkalosis, congestive heart failure)&#xD;
&#xD;
          -  Urine pH &gt; 7.0&#xD;
&#xD;
          -  Serum sodium &gt;150mmol/L&#xD;
&#xD;
          -  Blood pressure &gt;180/100mgHg&#xD;
&#xD;
          -  Severe hypokalaemia (K&lt;3.0mmol/L)&#xD;
&#xD;
          -  Inability to grant informed consent&#xD;
&#xD;
          -  Severe hypocalcaemia (Cai &lt;0.8 mmol/L)&#xD;
&#xD;
          -  Pregnant or lactating and breast-feeding women&#xD;
&#xD;
          -  Unwilling to use contraception&#xD;
&#xD;
          -  Patient is on a medication that may interact with sodium bicarbonate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlies Ostermann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlies Ostermann</last_name>
    <phone>02071883038</phone>
    <email>Marlies.Ostermann@gstt.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gill Arbane</last_name>
      <phone>02071887188</phone>
      <phone_ext>83036</phone_ext>
      <email>Gill.Arbane@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marlies Ostermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuttha Lumlertgul</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

